Ataluren for drug‐resistant epilepsy in nonsense variant‐mediated Dravet syndrome and CDKL5 deficiency disorder

Orrin Devinsky, LaToya King, Judith Bluvstein, Daniel Friedman

Open source

DOI
10.1002/acn3.51306
Published
2021-02-04
Container
Annals of Clinical and Translational Neurology
Publisher
Wiley
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1002/acn3.51306,
  title = {Ataluren for drug‐resistant epilepsy in nonsense variant‐mediated Dravet syndrome and CDKL5 deficiency disorder},
  author = {Orrin Devinsky and LaToya King and Judith Bluvstein and Daniel Friedman},
  year = {2021},
  journal = {Annals of Clinical and Translational Neurology},
  doi = {10.1002/acn3.51306},
  url = {https://doi.org/10.1002/acn3.51306}
}

RIS

TY  - JOUR
TI  - Ataluren for drug‐resistant epilepsy in nonsense variant‐mediated Dravet syndrome and CDKL5 deficiency disorder
AU  - Orrin Devinsky
AU  - LaToya King
AU  - Judith Bluvstein
AU  - Daniel Friedman
PY  - 2021
JO  - Annals of Clinical and Translational Neurology
DO  - 10.1002/acn3.51306
UR  - https://doi.org/10.1002/acn3.51306
ER  - 

APA

Devinsky, O., King, L., Bluvstein, J., & Friedman, D. (2021). Ataluren for drug‐resistant epilepsy in nonsense variant‐mediated Dravet syndrome and CDKL5 deficiency disorder. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.51306

Source records